ATAI Life Sciences and Beckley Psytech report positive Phase 2a data for BPL-003 in treatment-resistant depression

ATAI Life Sciences N.V.

Mean MADRS reduction of 13.3 points at Day 2 after first 8 mg dose; further reduction to 19.0 points after second 12 mg dose at Week 3.
Remitter rates doubled to 50% at Week 8 (6 weeks after second dose) from 25% after initial dose; 42% at Week 12.
All adverse events mild to moderate; no severe or serious drug-related adverse events reported.
Patients met discharge readiness within two hours after each dose; Phase 3 initiation expected H1 2026 pending FDA feedback.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.